X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/19/2866078/33039/en/ProQR-Achieves-Successful-Defense-of-New-Challenge-to-its-Axiomer-IP-Portfolio.html
https://www.globenewswire.com//news-release/2024/03/13/2845299/33039/en/ProQR-Announces-Year-End-2023-Operating-and-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/15/2829825/33039/en/ProQR-Announces-Japanese-Axiomer-Patent-Upheld-Following-Opposition-Against-Its-Leading-IP-Estate-for-ADAR-mediated-RNA-Editing.html
https://www.globenewswire.com//news-release/2024/01/19/2812237/33039/en/ProQR-Highlights-New-Platform-Data-from-Presentation-on-Axiomer-RNA-Editing-Technology-at-Deaminet-2024.html
https://www.globenewswire.com//news-release/2024/01/05/2804566/33039/en/ProQR-and-Rett-Syndrome-Research-Trust-Join-Forces-with-Axiomer-RNA-Editing-Collaboration.html
https://www.globenewswire.com//news-release/2023/12/08/2793148/33039/en/ProQR-Therapeutics-Announces-Transaction-Completed-for-Th%C3%A9a-to-Acquire-Sepofarsen-and-Ultevursen-Ophthalmic-Assets.html
https://www.globenewswire.com//news-release/2023/11/07/2774889/33039/en/ProQR-Announces-Third-Quarter-2023-Operating-and-Financial-Results.html
https://www.globenewswire.com//news-release/2023/11/06/2773905/33039/en/ProQR-Strengthens-Leading-Intellectual-Property-Estate-for-ADAR-mediated-RNA-Editing.html
https://www.globenewswire.com//news-release/2023/09/28/2751127/33039/en/ProQR-Announces-Participation-in-the-Chardan-7th-Annual-Genetic-Medicines-Conference.html
https://www.globenewswire.com//news-release/2023/09/27/2750241/33039/en/ProQR-Therapeutics-Provides-Update-on-Ophthalmic-Assets.html
Market Place
Share 
